Table 10.1.1.5 Open in new tab...

Table 10.1.1.5

Controlled medium-term and long-term studies of growth hormone-releasing hormone (GHRH) and GH-secretagogue treatment in healthy elderly subjects

Author	Design	Duration	Drug	Subjects	Results	Side effects
Khorram, 1997 (50)	Placebo controlled	16 W	[Nle²⁷]GHRH(1–29)-NH₂	males and females, 19 (55–71 years)	↑ GH, IGF-1, LBM skin thickness → FM	Transient hyperlipidaemia
Nass, 2008 (51)	Placebo controlled	1 Y	MK677	males and females, 65 (60–81 years)	↑ GH, IGF-1, LBM	↑ FPG, IR
White, 2009 (52)	Placebo controlled	1 Y	Capromorelin	males and females, 395 (65–84 years)	↑ GH, IGF-1, LBM, functional effects	Fatigue, insomnia ↑ FPG, IR

Author

Design

Duration

Drug

Subjects

Results

Side effects

Khorram, 1997 (50)

Placebo controlled

16 W

[Nle²⁷]GHRH(1–29)-NH₂

males and females, 19 (55–71 years)

↑ GH, IGF-1, LBM skin thickness → FM

Transient hyperlipidaemia

Nass, 2008 (51)

Placebo controlled

1 Y

MK677

males and females, 65 (60–81 years)

↑ GH, IGF-1, LBM

↑ FPG, IR

White, 2009 (52)

Placebo controlled

1 Y

Capromorelin

males and females, 395 (65–84 years)

↑ GH, IGF-1, LBM, functional effects

Fatigue, insomnia

↑ FPG, IR

↑, increased; →, unchanged.

D, days; W, weeks; FM, fat mass; FPG, fasting plasma glucose; LBM, lean body mass; IR, insulin resistance.